This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amgen Goes to Turkey, Loses Biotech Cred

BOSTON ( TheStreet) -- Amgen (AMGN - Get Report) is saying "elveda" to the biotech sector.

That's Turkish for "goodbye." With the $700 million purchase of Turkey's Mustafa Nevzat Pharmaceuticals, a maker of generic drugs, Amgen's claim as "the world's largest biotech company" no longer holds much meaning.

Amgen has graduated to become a "pharmaceutical company" joining the ranks of Merck (MRK - Get Report), Bristol-Myers Squibb (BMY - Get Report) and Pfizer (PFE).

"When you buy a generics company, it's not a biotech," says J.P. Morgan biotech analyst Geoff Meacham. "You have then shifted the focus from innovative products for specialty markets to marketing breadth for a wider audience i.e. a pharma."

But Meacham will continue to cover Amgen, illustrating the increasingly fuzzy divide between what investors consider pharmaceuticals and biotech. The differences between the two camps today have become more a matter of semantics than science.

Traditionally, a biotech company was one that genetically altered living organisms -- animal cells mostly -- to produce biological, or protein-based, injectable drugs. Pharmaceutical companies, on the other hand, used chemical processes -- akin to a well-defined chemical recipe -- to produce drugs, often in pill form.

Rules are always made to be broken, even in biotech. Gilead Sciences (GILD - Get Report) doesn't use a biologic process to manufacture its HIV drugs, but investors consider the company to be a biotech bellwether, along with Biogen Idec (BIIB) and Celgene (CELG - Get Report) (whose leading cancer drug Revlimid is also a pill.)

The death of George Rathmann, Amgen's first CEO, is a reminder that the company's DNA is grounded in biotech. Amgen developed two of the most successful biologic drugs in history -- the anemia drug Epogen and Neupogen, which treats chemotherapy side effects.

Yet Amgen is also a victim of its success. With annual revenues of $15.5 billion last year, meaningful top-line growth has become harder to achieve. Amgen continues to grow earnings year over year but needs the assistance of cost cuts and financial engineering to do so. Last year, Amgen became the first "biotech" firm to pay shareholders a dividend. Drug patent cliffs and the subsequent loss of revenue, once a worry only of pharmaceutical companies, is now also an issue Amgen is confronting.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMGN $176.71 2.90%
BMY $65.65 1.80%
CELG $131.33 -0.42%
GILD $117.87 -0.02%
MRK $58.99 0.80%

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs